X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CPX-POM (fosciclopirox) is a patented, parentally administered prodrug of a commercially available topical antifungal agent, ciclopirox. It is under phase 1/2 clinical development for the treatment of bladder cancer and Acute Myeloid Leukemia (AML).
Lead Product(s): Fosciclopirox
Therapeutic Area: Oncology Product Name: CPX-POM
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CicloMed LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Under the terms of co-development agreement, CicloMed holds the responsibility for executing clinical trial operations while Notable is focused on optimizing Notable’s predictive precision medicine platform with the goal of assessing patient responsiveness to fosciclopirox.
Lead Product(s): Fosciclopirox,Cytarabine
Therapeutic Area: Oncology Product Name: CPX-POM
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CicloMed LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
